FDA and EU AI Act Shape Life Sciences Industry's AI Adoption and Data Harmonization
The life sciences industry is undergoing a significant transformation in 2026, moving from experimental AI pilots to integrating artificial intelligence into core operations. This shift is driven by the need for measurable business value, operational efficiency, and clinical breakthroughs. A central challenge is clinical data harmonization, which involves restructuring how trial data is ingested, mapped, and analyzed from various sources like electronic data capture systems, electronic health records, and wearables. Regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Union, are actively establishing frameworks to ensure patient safety, efficacy, and ethical deployment of AI. The FDA has issued draft guidance on 'Considerations for the Use of Artificial Intelligence to Support Regulatory Decision Making for Drug and Biological Products,' emphasizing reviewable, evidence-centric outputs with transparent reasoning. Concurrently, the EU AI Act, the world's first comprehens...
